Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Income from Continuing OperationsIncome towards Parent CompanyNet Income towards Common StockholdersOperating ExpensesOperating IncomeOther Operating ExpensesProfit After TaxResearch & DevelopmentRevenueSelling, General & AdministrativeShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)
Others
Ratios

Immunome (IMNM) Revenue (2023 - 2025)

Immunome (IMNM) has disclosed Revenue for 3 consecutive years, with $4.0 million as the latest value for Q2 2025.

  • For the quarter ending Q2 2025, Revenue rose 69.84% year-over-year to $4.0 million, compared with a TTM value of $6.9 million through Dec 2025, down 23.23%, and an annual FY2025 reading of $6.9 million, down 23.23% over the prior year.
  • Revenue was $4.0 million for Q2 2025 at Immunome, up from $2.9 million in the prior quarter.
  • Across five years, Revenue topped out at $4.3 million in Q2 2023 and bottomed at $1.0 million in Q1 2024.
  • Average Revenue over 3 years is $3.0 million, with a median of $2.9 million recorded in 2024.
  • The sharpest move saw Revenue plummeted 56.47% in 2024, then skyrocketed 184.35% in 2025.
  • Year by year, Revenue stood at $3.8 million in 2023, then decreased by 28.44% to $2.7 million in 2024, then skyrocketed by 46.64% to $4.0 million in 2025.
  • Business Quant data shows Revenue for IMNM at $4.0 million in Q2 2025, $2.9 million in Q1 2025, and $2.7 million in Q4 2024.